Han Eol Jeong

1.2k total citations
56 papers, 380 citations indexed

About

Han Eol Jeong is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Infectious Diseases. According to data from OpenAlex, Han Eol Jeong has authored 56 papers receiving a total of 380 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Cardiology and Cardiovascular Medicine, 10 papers in Endocrinology, Diabetes and Metabolism and 8 papers in Infectious Diseases. Recurrent topics in Han Eol Jeong's work include Diabetes Treatment and Management (9 papers), Pharmacovigilance and Adverse Drug Reactions (6 papers) and Tuberculosis Research and Epidemiology (5 papers). Han Eol Jeong is often cited by papers focused on Diabetes Treatment and Management (9 papers), Pharmacovigilance and Adverse Drug Reactions (6 papers) and Tuberculosis Research and Epidemiology (5 papers). Han Eol Jeong collaborates with scholars based in South Korea, Canada and United Kingdom. Han Eol Jeong's co-authors include Ju‐Young Shin, Kristian B. Filion, Yunha Noh, Hyesung Lee, Sungho Bea, Sohee Park, Hyun Joon Shin, Yeon‐Hee Baek, Oriana Hoi Yun Yu and Dong Keon Yon and has published in prestigious journals such as PLoS ONE, Diabetes Care and Clinical Infectious Diseases.

In The Last Decade

Han Eol Jeong

51 papers receiving 375 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Han Eol Jeong South Korea 12 80 66 59 56 55 56 380
Satyajeet Roy United States 13 78 1.0× 34 0.5× 47 0.8× 83 1.5× 67 1.2× 42 433
Stephanie M. Toth‐Manikowski United States 10 74 0.9× 58 0.9× 45 0.8× 50 0.9× 23 0.4× 16 405
Fariba Samadian Iran 11 38 0.5× 82 1.2× 59 1.0× 51 0.9× 96 1.7× 30 426
Lu Cheng China 10 57 0.7× 29 0.4× 121 2.1× 70 1.3× 99 1.8× 36 562
Juan Erviti Spain 13 50 0.6× 97 1.5× 63 1.1× 106 1.9× 72 1.3× 43 570
Amit Goyal United States 9 65 0.8× 29 0.4× 45 0.8× 95 1.7× 76 1.4× 42 569
Osama Ishtiaq Pakistan 11 217 2.7× 30 0.5× 45 0.8× 47 0.8× 59 1.1× 29 495
Maria Giuseppa Sullo Italy 11 105 1.3× 33 0.5× 42 0.7× 91 1.6× 29 0.5× 22 397
Eun Mi Chun South Korea 14 29 0.4× 34 0.5× 40 0.7× 83 1.5× 73 1.3× 49 513

Countries citing papers authored by Han Eol Jeong

Since Specialization
Citations

This map shows the geographic impact of Han Eol Jeong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Han Eol Jeong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Han Eol Jeong more than expected).

Fields of papers citing papers by Han Eol Jeong

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Han Eol Jeong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Han Eol Jeong. The network helps show where Han Eol Jeong may publish in the future.

Co-authorship network of co-authors of Han Eol Jeong

This figure shows the co-authorship network connecting the top 25 collaborators of Han Eol Jeong. A scholar is included among the top collaborators of Han Eol Jeong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Han Eol Jeong. Han Eol Jeong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lee, Hyesung, Sungho Bea, Han Eol Jeong, et al.. (2025). Safety of combination therapy of azilsartan medoxomil and amlodipine: a population-based cohort study. Epidemiology and Health. 47. e2025029–e2025029.
2.
Cho, Yoosun, Eun Kyung Park, Yoosoo Chang, et al.. (2024). Concordant and discordant breast density patterns by different approaches for assessing breast density and breast cancer risk. Breast Cancer Research and Treatment. 210(1). 105–114. 1 indexed citations
3.
Bea, Sungho, et al.. (2024). Evaluation of the Regulatory Required Post-Authorization Safety Study for Propacetamol: Nested Case-Control and Case-Time-Control Studies. Yonsei Medical Journal. 65(2). 120–120. 1 indexed citations
4.
Bea, Sungho, Han Eol Jeong, Kristian B. Filion, et al.. (2023). Outcomes of SGLT-2i and GLP-1RA Therapy Among Patients With Type 2 Diabetes and Varying NAFLD Status. JAMA Network Open. 6(12). e2349856–e2349856. 9 indexed citations
5.
6.
Choi, Eun‐Young, Han Eol Jeong, Yunha Noh, et al.. (2023). Neonatal and maternal adverse outcomes and exposure to nonsteroidal anti-inflammatory drugs during early pregnancy in South Korea: A nationwide cohort study. PLoS Medicine. 20(2). e1004183–e1004183. 12 indexed citations
7.
Jeong, Han Eol, et al.. (2023). Dynamic Patterns and Persistence of Anticoagulation Therapy in Patients with Venous Thromboembolism in South Korea: A Nationwide Cohort Study. Thrombosis and Haemostasis. 124(2). 152–162. 2 indexed citations
8.
Park, Sohee, Han Eol Jeong, Hyesung Lee, Seng Chan You, & Ju‐Young Shin. (2023). Association of sodium-glucose cotransporter 2 inhibitors with post-discharge outcomes in patients with acute heart failure with type 2 diabetes: a cohort study. Cardiovascular Diabetology. 22(1). 191–191. 7 indexed citations
9.
10.
Noh, Yunha, Han Eol Jeong, Eun‐Young Choi, et al.. (2023). Association Between Proton Pump Inhibitor Use During Early Pregnancy and Risk of Congenital Malformations. JAMA Network Open. 6(1). e2250366–e2250366. 12 indexed citations
11.
12.
Bea, Sungho, Han Eol Jeong, Sohee Park, et al.. (2023). Sodium-Glucose Cotransporter 2 Inhibitors vs Incretin-Based Drugs and Risk of Fractures for Type 2 Diabetes. JAMA Network Open. 6(9). e2335797–e2335797. 15 indexed citations
13.
Yu, Ya‐Hui, Han Eol Jeong, Robert W. Platt, et al.. (2022). Challenges in evaluating treatments for COVID-19: The case of in-hospital anticoagulant use and the risk of adverse outcomes. Frontiers in Pharmacology. 13. 1034636–1034636. 2 indexed citations
14.
Baek, Yeon‐Hee, Yunha Noh, Han Eol Jeong, et al.. (2022). Analytical Approaches to Reduce Selection Bias in As-Treated Analyses with Missing In-Hospital Drug Information. Drug Safety. 45(10). 1057–1067. 1 indexed citations
15.
Noh, Yunha, et al.. (2021). Association Between DPP-4 Inhibitors and COVID-19–Related Outcomes Among Patients With Type 2 Diabetes. Diabetes Care. 44(4). e64–e66. 33 indexed citations
16.
Kim, Ju Hwan, et al.. (2021). Treatment pattern in postmenopausal women with osteoporosis: a population-based cohort study in South Korea. Journal of Bone and Mineral Metabolism. 40(1). 109–119. 3 indexed citations
17.
Man, Kenneth K. C., Shih‐Chieh Shao, Han Eol Jeong, et al.. (2021). Cardiovascular and metabolic risk of antipsychotics in children and young adults: a multinational self-controlled case series study. Epidemiology and Psychiatric Sciences. 30. e65–e65. 5 indexed citations
18.
Jeong, Han Eol, Hyesung Lee, Hyun Joon Shin, et al.. (2020). Association Between Nonsteroidal Antiinflammatory Drug Use and Adverse Clinical Outcomes Among Adults Hospitalized With Coronavirus 2019 in South Korea: A Nationwide Study. Clinical Infectious Diseases. 73(11). e4179–e4188. 27 indexed citations
19.
20.
Baek, Yeon‐Hee, Sang Jun Park, Sohyun Jeong, et al.. (2018). Signal Detection Between Fluoroquinolone Use and the Risk of Rhegmatogenous Retinal Detachment: Sequence Symmetry Analysis Using Nationwide South Korean Healthcare Database Between 2004 and 2015. Clinical Drug Investigation. 38(12). 1179–1188. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Satyajeet Roy Breakdown of academic impact, for papers by Stephanie M. Toth‐Manikowski Breakdown of academic impact, for papers by Fariba Samadian Breakdown of academic impact, for papers by Lu Cheng Breakdown of academic impact, for papers by Juan Erviti Breakdown of academic impact, for papers by Amit Goyal Breakdown of academic impact, for papers by Osama Ishtiaq Breakdown of academic impact, for papers by Maria Giuseppa Sullo Breakdown of academic impact, for papers by Eun Mi Chun
Rankless by CCL
2026